The Tamoxifen and Exemestane Trial (TEXT) and Suppression of Ovarian Function Trial (SOFT) randomized trials compared adjuvant AI (exemestane) plus ovarian suppression with adjuvant tamoxifen plus ovarian suppression for a period of 5 years in premenopausal women with hormone receptor-positive breast cancers. Here, NR4A1 is linked to breast carcinoma.